Publications by authors named "R Matthew Miller"
Background: Randomized clinical trials have shown that semaglutide is associated with a clinically relevant reduction in body weight and a lower risk of adverse cardiovascular events in those who are overweight or obese with a history of cardiovascular disease but no diabetes. The objective of this study was to assess the cost-effectiveness of semaglutide for this indication.
Methods: A decision analytic Markov model was used to compare the lifetime benefits and costs of semaglutide 2.
In the military, combat wound infections can progress rapidly to life-threatening sepsis. The discovery of effective small-molecule drugs to prevent and/or treat sepsis is a priority. To identify potential sepsis drug candidates, we used an optimized larval zebrafish model of endotoxicity/sepsis to screen commercial libraries of drugs approved by the U.
View Article and Find Full Text PDFArticle Synopsis
- High-dose methotrexate (MTX) can lead to serious complications like acute kidney injury (AKI), neutropenia, and liver damage, but glucarpidase, an enzyme that breaks down MTX, shows potential benefits.
- In a study of 708 patients with MTX-AKI across 28 cancer centers, those receiving glucarpidase had a significantly higher chance of kidney recovery and faster recovery times compared to those who did not receive the treatment.
- Additionally, glucarpidase treatment was associated with lower rates of severe neutropenia and liver enzyme elevation, but there was no notable difference in mortality rates between the two groups.
Background: Observational data have suggested that patients with moderate to severe ischemia benefit from revascularization. However, this was not confirmed in a large, randomized trial.
Objectives: Using a contemporary, multicenter registry, the authors evaluated differences in the association between quantitative ischemia, revascularization, and outcomes across important subgroups.